<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142904</url>
  </required_header>
  <id_info>
    <org_study_id>2021-1798</org_study_id>
    <nct_id>NCT05142904</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules</brief_title>
  <acronym>RABITO</acronym>
  <official_title>Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amsterdam UMC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare treatment of hyperthyroidism with radiofrequency&#xD;
      ablation or I-131 for solitary autonomous thyroid nodules.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2021</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre 1:1 randomized clinical trial where patients are allocated to either radiofrequency ablation (RFA) or radioactive iodine (RAI) (I-131). Patients who are not suitable for randomization (e.g. no informed consent or contra-indication for RFA) are asked for consent to participate in a prospective cohort where participants are asked to fill out questionaires and data is collected.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypothyroidism</measure>
    <time_frame>1 year post-intervention</time_frame>
    <description>Incidence of hypothyroidism (defined as TSH above normal values with/without decreased FT4 and/or FT3 levels)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate</measure>
    <time_frame>1 year post-intervention</time_frame>
    <description>Medication-free normalization of TSH, FT4 and FT3 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid nodule volume</measure>
    <time_frame>Baseline, 6 and 12 months post-intervention</time_frame>
    <description>Volume of thyroid nodule assessed by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related adverse events</measure>
    <time_frame>6 weeks and 3, 6 and 12 months post-intervention</time_frame>
    <description>Number of adverse and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid related quality of life</measure>
    <time_frame>Baseline, 6 and 12 months after intervention</time_frame>
    <description>Thyroid related quality of life assessed by ThyPro questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Baseline, 6 weeks, and 3, 6, 9 and 12 months post-intervention</time_frame>
    <description>Determined as the incremental costs in Euros per quality adjusted life year (QALY)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of thyroid function</measure>
    <time_frame>Baseline, 1 and 6 weeks, 3, 6, 9 and 12 months post-intervention with an extension of follow-up up to 5 years.</time_frame>
    <description>Assessed by TSH, FT4 and FT3 an medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term patient satisfaction</measure>
    <time_frame>1 week and 1 year post-intervention</time_frame>
    <description>Assessed by interviews, satisfaction questionnaire and pain scoring by visual analog scale (VAS, a scale ranging from 0-10 represented as a line with 0 on the left end indicating 'no pain' and 10 on the right end, indicating 'the worst pain').</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health outcomes and quality of life</measure>
    <time_frame>Baseline, 6 and 12 months after intervention</time_frame>
    <description>Assessed by European Quality of Life-5 Dimensions (EQ-5D) questionnaire. ( questions in 5 dimensions with 3 response levels, a higher score representing a worse outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Use of hospital resources</measure>
    <time_frame>1 year post-intervention</time_frame>
    <description>According to medical records</description>
  </other_outcome>
  <other_outcome>
    <measure>Medical consumption</measure>
    <time_frame>1 year post-intervention</time_frame>
    <description>iMCQuestionnaire (institute for medical technology assessment medical consumption questionnaire)</description>
  </other_outcome>
  <other_outcome>
    <measure>Use of healthcare resources</measure>
    <time_frame>1 year post-intervention</time_frame>
    <description>iPCQuestionnaire (institute for medical technology assessment productivity cost questionnaire)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative cost</measure>
    <time_frame>1 year post-intervention</time_frame>
    <description>Based on Rijnstate price estimates</description>
  </other_outcome>
  <other_outcome>
    <measure>Fractional nodal uptake</measure>
    <time_frame>1 year post-intervention</time_frame>
    <description>Assessed by I-123 or I-131 scintigraphy</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment related auto-immunity</measure>
    <time_frame>Baseline and 1 year post-intervention</time_frame>
    <description>Assessed by thyroid antibodies</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Thyroid Nodule, Toxic or With Hyperthyroidism</condition>
  <condition>Autonomous Thyroid Function</condition>
  <condition>Thyroid Nodule; Hyperthyroidism</condition>
  <condition>Radiofrequency Ablation</condition>
  <condition>Iodine Hyperthyroidism</condition>
  <condition>Iodine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to the radiofrequency ablation (RFA) arm will undergo RFA under local anaesthesia with the moving-shot technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radioactive iodine, study protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to this arm will undergo treatment with radioactive iodine (I-131) according to a standardized dose-calculation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radioactive iodine, cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group contains patients who are not randomized and have given informed consent undergo treatment with radioactive iodine (I-131) according to local standard (e.g. fixed dose or dose-calculation based on iodine uptake and thyroid nodule mass).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <other_name>RFA</other_name>
    <other_name>Ultrasound-guided radiofrequency ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radioactive iodine</intervention_name>
    <description>I-131 according to standardized doses-calculation.</description>
    <arm_group_label>Radioactive iodine, study protocol</arm_group_label>
    <other_name>I-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radioactive iodine</intervention_name>
    <description>I-131 according to local standard.</description>
    <arm_group_label>Radioactive iodine, cohort</arm_group_label>
    <other_name>I-131</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Hyperthyroidism or subclinical hyperthyroidism caused by a solitary hyperactive&#xD;
             thyroid nodule (HTN), either located in an otherwise normal thyroid gland, or in a&#xD;
             multinodular goitre (MNG), with a diagnosis based on the following characteristics:&#xD;
&#xD;
               -  Blood TSH level below the lower limit of normal, and associated with either&#xD;
                  normal or elevated FT4 and FT3 levels&#xD;
&#xD;
               -  Anti-TSH antibody negative&#xD;
&#xD;
               -  Solitary HTN confirmed by a diagnostic I-123 scintigraphy, corresponding with a&#xD;
                  well demarcated thyroid node on ultrasound, cystic degeneration &lt; 75%, nodule&#xD;
                  size &lt;50 mm.&#xD;
&#xD;
          -  Treatment with RAI indicated, and eligible for RFA treatment&#xD;
&#xD;
          -  Signed informed consent Patients who are ineligible for randomization due to&#xD;
             unsuitability for RFA, may be eligible for the RAI cohort group.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multifocal HTN&#xD;
&#xD;
          -  HTN &gt; 50 mm&#xD;
&#xD;
          -  Presence of a medical device susceptible to disturbances caused by RFA generated&#xD;
             currents&#xD;
&#xD;
          -  Patients with physical or behavioural disorders that preclude safe isolation in&#xD;
             radiation protection rooms, or safe RFA procedure under local anesthesia&#xD;
&#xD;
          -  Patients with dysphagia, oesophageal stenosis, active gastritis, gastric erosion, a&#xD;
             peptic ulcer or impaired gastro-intestinal motility&#xD;
&#xD;
          -  Uncorrectable haemorrhagic diathesis&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Manon MD van der Meeren, MD</last_name>
    <phone>088 005 8888</phone>
    <email>mvandermeeren@rijnstate.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wim Oyen, Prof.</last_name>
    <phone>088 005 8888</phone>
    <email>RABITOstudie@rijnstate.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manon van der Meeren, MD</last_name>
      <phone>088 005 8888</phone>
      <email>mvandermeeren@rijnstate.nl</email>
    </contact>
    <contact_backup>
      <last_name>Wim Oyen, Prof.</last_name>
      <phone>088 005 8888</phone>
      <email>RABITOstudie@rijnstate.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Wim Oyen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Joosten, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manon MD van der Meeren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pim de Graaf, PhD</last_name>
      <phone>020 444 4444</phone>
      <email>p.degraaf@amsterdamumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Koen Dreijerink, MD</last_name>
      <phone>020 444 4444</phone>
      <email>k.dreijerink@amsterdamumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Pim de Graaf, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Nodule</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

